title: International guidelines on access to biologic therapy: why the differences and which is best?
authors.affiliation: Derbyshire Royal Infirmary, Department of Rheumatology, Derby, UK. chris.deighton@derbyhospitals.nhs.uk
authors.forename: Chris
authors.initials: C
authors.lastname: Deighton
authors.forename: Kimme
authors.initials: K
authors.lastname: Hyrich
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001691:Biological Therapy; D006297:Health Services Accessibility; D006801:Humans; D007391:International Cooperation; D017410:Practice Guidelines as Topic; D012219:Rheumatology / Q000191:economics / Q000379:methods*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha